Today
-3.45%
5 Days
-12.12%
1 Month
-5.55%
6 Months
+355.49%
Year to Date
+657.44%
1 Year
+801.78%
• Moderna shares dropped following profit-taking after the recent Analyst Day presentation. • High capital intensity for oncology pivot raised investor concerns over cash burn. • Strong prior stock gains and lack of near-term catalysts triggered selling.
• Moderna shares declined amid skepticism over respiratory vaccine commercial rollouts and competition. • High R&D spending and pipeline investments raised concerns over operational profitability. • Technical indicators show a MACD buy signal and neutral RSI condition.
• Eli Lilly reported an annual revenue of $65.18B and net profit of $20.64B. • Tirzepatide portfolio expansion and improved manufacturing capacity drive strong institutional investor sentiment. • Technical indicators including MACD and Williams %R currently suggest a buy signal.
• Moderna reported unexpected third-quarter profitability driven by strong Spikevax vaccine demand. • Management upgraded full-year revenue guidance amid ongoing operational discipline and cost-containment. • Late-stage oncology pipeline progress and constructive regulatory updates supported positive sentiment.
Health Canada authorized Moderna’s mFLUSIVA influenza vaccine and mCOFLU combined influenza and COVID-19 vaccine for adults aged 50 and older.
• Vertex missed EPS expectations despite higher year-over-year third-quarter revenue. • Operating expenses and Crinetics integration costs pressured third-quarter profitability. • Management raised full-year revenue guidance incorporating the Crinetics acquisition.
Moderna (MRNA) Q3 2026 Earnings Call: Revenue Up 29%, Outlook Raised


| Shareholders | Proportion |
|---|---|
| Fidelity Management & Research Company LLC | 6.74% |
| Vanguard Capital Management, LLC | 5.76% |
| BlackRock Institutional Trust Company, N.A. | 5.30% |
| Baillie Gifford & Co. | 5.04% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 45.49% |
| Investment Advisor/Hedge Fund | 14.13% |
| Hedge Fund | 10.11% |
| Corporation | 4.56% |
Related Instruments